Advanced oxidation protein products in obese women: Its relation to insulin resistance and resistin

Clinical and Experimental Medicine

Volumn 7, Issue 4, 2007, Pages 173-178

  Kocak H ^a   Oner Iyidogan Y ^b   Gurdol F ^a   Oner P ^a   Suzme R ^a   Esin, D ^c   Issever H ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

^b ISTANBUL UNIVERSITY   (Turkey)

^c ISTANBUL TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

AOPP; Cytokine; Insulin resistance; Resistin; Type 2 diabetes

Indexed keywords

ADVANCED OXIDATION PROTEIN PRODUCT; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ADIPOCYTE; ADULT; AGED; ARTICLE; BODY MASS; CORRELATION ANALYSIS; CYTOKINE PRODUCTION; FEMALE; GLUCOSE BLOOD LEVEL; HOMEOSTASIS; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MEASUREMENT; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OXIDATION; OXIDATIVE STRESS; PRIORITY JOURNAL; RISK FACTOR;

AGED; BLOOD PROTEINS; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; INSULIN RESISTANCE; INTERLEUKIN-6; MIDDLE AGED; OBESITY; OXIDATION-REDUCTION; RESISTIN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 38149044929     PISSN: 15918890     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10238-007-0143-x     Document Type: Article

References (39)

1. Cottam DR, Mattar SG, Barinas-Mitchell E et al (2004) The chronic inflammatory hypothesis for the morbidity associated with morbid obesity: implications and effects of weight loss. Obes Surg 14:589-600
2. Hotamisligil GS, Shargill NS, Spiegelman BM (1993) Adipose expression of tumor necrosis factor alpha: direct role in obesity-linked insulin resistance. Science 259:87-91
3. Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW (1999) C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 19:972-978
4. Hotamisligil GS, Budavari A, Murray D, Spiegelman BM (1994) Reduced tyrosine kinase activity of the insulin receptor in obesity-diabetes. Central role of tumor necrosis factor-alpha. J Clin Invest 94:1543-1549
5. Mito N, Hosoda T, Kato C, Sato K (2000) Change of cytokine balance in diet-induced obese mice. Metabolism 49:1295-1300
6. Mooradian AD, Reed RI, Meredith KE, Scuderi P (1991) Serum levels of tumor necrosis factor and IL-1a and IL-1b in diabetic patients. Diabetes Care 14:63-65
7. Carey AL, Bruce CR, Sacchetti M et al (2004) Interleukin-6 and tumor necrosis factor-alpha are not increased in patients with Type 2 diabetes: evidence that plasma interleukin-6 is related to fat mass and not insulin responsiveness. Diabetologia 47:1029-1037
8. Bastard JP, Maachi M, Lagathu C et al (2006) Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw 17:4-12
9. Vettor R, Milan G Rossato M, Federspil G (2005) Review article: adipocytokines and insulin resistance. Aliment Pharmacol Ther 22[Suppl 2]:3-10
10. Lee JH, Chan JL, Yiannakouris N et al (2003) Circulating resistin levels are not associated with obesity or insulin resistance in humans and are not regulated by fasting or leptin administration: cross-sectional and interventional studies in normal, insulin-resistant, and diabetic subjects. J Clin Endocrinol Metab 88:4848-4856
11. Savage DB, Sewter CP, Klenk ES et al (2001) Resistin/Fizz 3 expression: in relation to obesity and peroxisome proliferator activated receptor-gamma action in humans. Diabetes 50:2199-2202
12. Zhang JL, Qin YW, Zheng X et al (2003) Serum resistin level in essential hypertension patients with different glucose tolerance. Diabetic Med 20:828-831
13. Kusminski CM, McTernan PG, Kumar S (2005) Role of resistin in obesity, insulin resistance and Type II diabetes. Clin Sci (Lond) 109:243-256
14. Steppan CM, Bailey ST, Bhat S et al (2001) The hormone resistin links obesity to diabetes. Nature 409:307-312
15. Fantuzzi G (2005) Adipose tissue, adipokines and inflammation. J Allergy Clin Immunol 115:911-919
16. Chanchay S, Tungtrongchitr R, Harnroongroj T et al (2006) Plasma resistin, insulin concentration in non-diabetic and diabetic, overweight/obese Thai. Int J Vitam Nutr Res 76:125-131
17. Silha JV, Krsek M, Skrha JV et al (2003) Plasma resistin, adiponectin and leptin levels in lean and obese subjects: Correlations with insulin resistance. Eur J Endocrinol 149:331-335
18. Qi Y, Nie Z, Lee YS et al (2006) Loss of resistin improves glucose homeostasis in leptin deficiency. Diabetes 55:3083-3090
19. Yaturu S, Daberry RP, Rains J, Jain S (2006) Resistin and adiponectin levels in subjects with coronary artery disease and type 2 diabetes. Cytokine 34:219-223
20. Kougias P, Chai H, Lin PH et al (2005) Adipocyte-derived cytokine resistin causes endothelial dysfunction of porcine coronary arteries. J Vasc Surg 41:691-698
21. Bo S, Gambino R, Pagani A et al (2005) Relationships between human serum resistin, inflammatory markers and insulin resistance. Int J Obes 29:1315-1320
22. Opara EC (2002) Oxidative stress, micronutrients, diabetes mellitus and its complications. J R Soc Health 122:28-34
23. Martin-Gallan P, Carrascosa A, Gussinye M, Dominguez C (2003) Biomarkers of diabetes-associated oxidative stress and antioxidant status in young diabetic patients with or without subclinical complications. Free Radic Biol Med 34:1563-1574
24. Gil-Del Valle L, Milian LC, Toledo A et al (2005) Altered redox status in patients with diabetes mellitus type I. Pharmacol Res 51:375-380
25. Davi G, Falco A, Patrono C (2005) Lipid peroxidation in diabetes mellitus. Antioxid Redox Signal 7:256-268
26. Furukawa S, Fujita T, Shimabukuro M et al (2004) Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 114:1752-1761
27. Witko-Sarsat V, Friedlander M, Capeiller-Blandin C (1996) AOPP as a novel marker of oxidative stress in uremia. Kidney Int 49:1304-1313
28. Kaluosava M, Skrha J, Zima T (2002) Advanced glycation end-products and advanced oxidation protein products in patients with diabetes mellitus. Physiol Res 51:597-604
29. Atabek ME, Keskin M, Yazici C et al (2006) Protein oxidation in obesity and insulin resistance. Eur J Pediatr 165:753-756
30. American Diabetes Association (2007) Diagnosis and classification of diabetes mellitus. Diabetes Care 30:S42-S47
31. Matthews DR, Hosker JP, Rudenski AS et al (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412-419
32. Osawa H, Yamada K, Onuma H et al (2004) The G/G genotype of a resistin single-nucleotide polymorphism at -420 increases type 2 diabetes mellitus susceptibility by inducing promoter activity through specific binding of Sp1/3. Am J Hum Genet 75:678-686
33. Gillery P (2001) Advanced glycation end products (AGEs), free radicals and diabetes. J Soc Biol 195:387-390
34. De Cristofaro R, Rocca B, Vitacolonna E et al (2003) Lipid and protein oxidation contribute to a prothrombotic state in patients with type 2 diabetes mellitus. J Thromb Haemost 1:250-256
35. Yudkin JS, Kumari M, Humpries SE, Mohammed-Ali V (2000) Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis 148:209-214
36. Tuttle HA, Davis-Gorman G, Goldman S et al (2004) Proinflammatory cytokines are increased in type 2 diabetic women with cardiovascular disease. J Diabetes Complications 18:343-351
37. Zinman B, Hanley AJ, Harris SB et al (1999) Circulating tumor necrosis factor-alpha concentrations in a native Canadian population with a high rate of type 2 diabetes mellitus. J Clin Endocrinol Metab 84:272-278
38. Hu FB, Meigs JB, Li TY et al (2004) Inflammatory markers and risk of developing type 2 diabetes in women. Diabetes 53:693-700
39. Sjöholm A, Nyström T (2006) Inflammation and the etiology of type 2 diabetes. Diabetes Metab Res Rev 22:4-10